RADX vs RNW vs RNAZ vs LNTH vs AGEN

For growth investors, Radiopharm Theranostics Limited (RADX) is the stronger pick with 1114% revenue growth year-over-year, versus 0.

5% for Lantheus Holdings, Inc. (LNTH). Lantheus Holdings, Inc. (LNTH) offers the better valuation at 26. 7x trailing P/E (17. 5x forward), making it the more compelling value choice. Analysts rate ReNew Energy Global Plc (RNW) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Lantheus Holdings, Inc.

(LNTH) is the cheapest at 26. 7x versus ReNew Energy Global Plc at 46. 9x. On forward P/E, ReNew Energy Global Plc is actually cheaper at 0. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Lantheus Holdings, Inc.

(LNTH) delivered a total return of +314. 2%, compared to -100. 0% for TransCode Therapeutics, Inc. (RNAZ). Over 10 years, the gap is even starker: LNTH returned +41. 9% versus RNAZ's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lantheus Holdings, Inc.

(LNTH) is the lower-risk stock at 0. 47β versus Agenus Inc. 's 2. 72β — meaning AGEN is approximately 480% more volatile than LNTH relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 6% for ReNew Energy Global Plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Radiopharm Theranostics Limited (RADX) is pulling ahead at 1114% versus 0.

5% for Lantheus Holdings, Inc. (LNTH). On earnings-per-share growth, the picture is similar: Agenus Inc. grew EPS 100. 0% year-over-year, compared to -21. 8% for Lantheus Holdings, Inc.. Over a 3-year CAGR, RADX leads at 643. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Lantheus Holdings, Inc.

(LNTH) is the more profitable company, earning 15. 2% net margin versus -1055. 3% for Radiopharm Theranostics Limited — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RNW leads at 53. 5% versus -1050. 6% for RADX. At the gross margin level — before operating expenses — RNW leads at 91. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ReNew Energy Global Plc (RNW) trades at 0.

4x forward P/E versus 17. 5x for Lantheus Holdings, Inc. — 17. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AGEN: 95. 5% to $7. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Lantheus Holdings, Inc.

(LNTH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 47)). Agenus Inc. (AGEN) carries a higher beta of 2. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LNTH: +41. 9%, AGEN: -94. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RADX (Healthcare) and RNW (Utilities) and RNAZ (Healthcare) and LNTH (Healthcare) and AGEN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: RADX is a small-cap high-growth stock; RNW is a small-cap high-growth stock; RNAZ is a small-cap quality compounder stock; LNTH is a small-cap quality compounder stock; AGEN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.